Aurigene's Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones

 Aurigene's Collaboration Programs with Endo Pharmaceuticals Reach Important
                                  Milestones

PR Newswire

BRIDGEWATER, New Jersey, April 22, 2013

BRIDGEWATER, New Jersey, April 22, 2013 /PRNewswire/ --

Aurigene and Endo entered into collaboration in 2009, for multiple integrated
drug discovery programs in the areas of Inflammation and Oncology.

 (Logo: http://photos.prnewswire.com/prnh/20130418/608115 )

In one of the programs, a novel selective dual kinase inhibitor, targeting
both the antigen receptor signalling and cytokine signalling pathways involved
in immune regulation for inflammatory disorders, has been chosen for
IND-enabling toxicology studies by Endo.

In a second program, targeting two different growth factor signalling pathways
in oncology, a novel class of compounds is being developed, and is in the late
lead optimization phase. This program has the potential to deliver multiple
candidates for clinical development, targeting several unmet needs for solid
tumors.

"We are pleased to be working with a really accomplished and ambitious team at
Endo, and these collaborative efforts have enabled us to aim at delivering
unique clinical candidates with a profile that is potentially significantly
differentiated in the clinic", remarked Dr. Murali Ramachandra, Sr Vice
President, Pre-clinical Biology, Aurigene.

"The programs being carried out at Aurigene are an integral part of Endo's
strategy to discover novel drug candidates that improve patient outcomes. We
are excited about the possibility for the current programs to be important
additions to our development pipeline" commented Dr. Sandeep Gupta, Senior
Vice President of Drug Discovery and Early Development at Endo.

About Aurigene

Aurigene is a Biotech focussed on building a robust pipeline of small molecule
and peptide therapeutics in the exciting areas of Cancer Metabolism,
Epigenetics and the TH17 pathway. Aurigene's most advanced programs in its
pipeline include several compounds expected to be in clinical development over
the next few months, for oncology, inflammation and anti-infective
indications. These are (a) PD-1 peptide therapeutics for oncology and
antibacterial indications; (b) A novel protease inhibitor for Osteo Arthritis
(DMOAD) and pain alleviation; (c) A differentiated FabI inhibitor with
potential for IV/ oral switch, for MRSA.

In addition, Aurigene works with Pharma companies on early stage
collaborations in integrated discovery partnerships. Aurigene, with over 500
scientists in its Indian and Malaysian laboratories, has collaborated with 6
of the top 10 pharma companies, in addition to partnerships with mid-sized
pharma companies and biotechs in the US and Europe.

For more information on Aurigene's collaboration business model, and its
pipeline, please visit the company's website at http://www.aurigene.com.

Media Contacts:
Mark Ravera, Head of Business Development, USA
Rajshree KT +91-40-4465-7777
Head Strategic Alliances, India
pr@aurigene.com

SOURCE Aurigene